Levamisole (LMS), the levoisomer of 2,3,5,6-tetrahydro-6-phenylimidazo [2, l-b] thiazole hydrochloride, has demonstrated immunoenhancing activities on mouse responsiveness to antigenic stimuli (1-4). This activity depended upon T-cell potentiation as evidenced by increased gra~-versus-host reaction when donors were treated by LMS (5), by accelerated rejection of isogeneic skin grafts (6, 7), or by enhanced levels of delayed hypersensitivity in LMS-treated mice (7). Sodium diethyldithiocarbamate, DTC, a noncyclic sulphur drug, induced similar responses (8). LMS effect can be transferred by a serum factor obtained from animals after treatment with LMS. In transfer experiments, this factor enforced immune responses to sheep red cells (SRC) in recipient mice and induced regression of tumor size in leukemic AKR mice, even when leukemic mice have failed to respond to treatment with LMS (9, 10). On the other hand, the impaired development of T ceils in nu/nu mice has been ascribed to lack of the maturation stimulus, or stimuli, normally provided by thymus factors (11-15).
In this report, we present evidences that LMS or DTC induce in vivo acquisition of specific T-cell markers by undifferentiated precursor lymphoid cells of thymusless nude mice and concomitantly induce functional immune activation. Also, that serum from treated nu/nu mice can transfer these in vivo activities and allow in vitro differentiation of precursor cells into T cells.
Materials and Methods
Healthy nu/nu mice from the Edinburgh strain (16) , obtained from the Centre de Sdlection des Animaux de Laboratoire (CNRS, Orldans, France), were maintained in an air-conditioned room and partially protected from environmental infections by Isocap filters (Iffa-Credo, l'Arbresle, France).
LMS or DTC were dissolved in pyrogen-free saline and subcutaneously administered in vol of 0.2 mt, at the doses indicated in the individual experiments. Doses of the drug were expressed in milligrams of the salt per kilogram body weight.
In in vivo assays, 5-to 6-wk-old female nu/nu mice were killed 4 days after a single drug administration. Any mouse showing evidence of liver disease (17) was discarded from the experiment. In vitro induction assays were performed for 2.5 h at 37°C in a humidified CO2 incubator in the absence or presence of LMS or DTC. Amounts of the drugs varied from 10 -s to 10 -~ mM/10 ~ lymphocytes per ml of medium. Expression ofT-cell antigens on the cell surface was tested on either in vitro or in vivo induced lymphocyte suspensions in the cytotoxicity assay (18), using Thy-l.2 and TL 1, 2, 3 antisera kindly provided by E. A. Boyse. Each cytotoxicity assay was performed in duplicate. Induction of an acquired functional (helper) activity was assayed on day 4 after immunization of nu/nu mice with SRC and simultaneous treatment with LMS or with DTC * This work was sponsored by the Institut National de la Recherche Medicale (no. 74. ) was used to detect contaminant endotoxin before in vitro addition or to in vivo injection, and any assay performed with a sample that resulted even questionable for trace amount of endotoxin was discarded from the experiment. Flotation of cell suspensions in bovine serum albumin (BSA) to obtain prothymocyteenriched populations was not used since available batches of BSA were contaminated with endotoxin-like products in the Limulus assay.
Results Our studies show that healthy nu/nu mice had few or no cells bearing T-cell markers in the absence of activation by an overt or remote administration of endotoxin (20) or by mouse hepatitis virus infection (17) . Under these conditions, T cells could be induced in vivo in healthy nu/nu mice by an injection of LMS or DTC (Table I ). In vivo induction of spleen prothymocyte differentiation by LMS or by DTC gave rise to cells of the TL-Thy 1 ÷ phenotype. This is the phenotype of peripheral T cells and of the medullary thymocyte. This fast induction of functional T cells takes place only in the spleen, suggesting prothymocytes are absent in lymph nodes (Table I ). The acquisition of a cytotypic T-cell surface marker after a single treatment with LMS or DTC compared favorably with the effects of repeatedly administering preparations from thymus (17, 20) . In contrast to the effects of thymopoietin (17, 21) , precursor cells from spleen ofnu/nu thymusless mice incubated with LMS or DTC did not differentiate into T cells (data not tabulated, as similar to controls).
Administration of LMS or DTC evoked in SRC-immunized nu/nu mice significant numbers of IgG-PFC which were not present in immunized but untreated control animals (Table II ). An early switch from IgM to IgG antibody synthesis is a known effect of activated T lymphocytes (22) . Therefore, present data confirm that LMS and DTC are in vivo able both to recruit and to activate the Tcell lineage (5-10). Inducing or immunostimulating in vivo activities of LMS or of DTC are likely associated with their sulphur moiety (8, 23) , since DTC is devoid of the imidazole ring.
Nu/nu mice treated with LMS produced a factor that was absent from serum of untreated mice. This factor allowed both in vitro induction of thymocyte differentiation and transfer of immune stimulation. Indeed, when precursor cells from spleen or bone marrow ofnu/nu mice were incubated in the presence of serum from LMS-treated nude mice, they express thymocyte markers (Table  III) . The inducing activity of serum from LMS-treated nu/nu mice could be compared to the in vitro efficiency of thymus extracts (17, 18, 20, 21) or of thymic serum factors (14, 15) . Functional activation was evidenced by a twofold enhancement of the immune response to SRC evoked by administering to C3H/He mice as little as 0.2 ml of serum from nu/nu mice treated with LMS (Table IV) Acquired functional activity was assayed on day 4 postimmunization and simultaneous s.c. treatment. All data are values for individual mice. Negative Limulus assays indicated less than 0.5 ng endotoxin per ml of injected suspensions. Note that, healthy nulnu mice, not contaminated by endotoxin or disease, did not demonstrate "background" PFC. <5, <5 0
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Induction assays were performed on 5 × 106 cells suspended in 1 ml of 1640 medium and incubated for 2.5 h at 37°C in a humidified CO~ incubator in the presence or absence of serum to be tested which was replaced in controls ("None" treatment) by 1% of IgG-free fetal calf serum. Normal mouse serum (NMS) was sampled on normal healthy 6-wk-old female nu/nu mice. LMStS was a pool of sera from female nu/nu mice collected 24 h after a treatment with 25 rng/kg LMS. Negative Limulus assays indicated less than 0. Pooled serum (LMS-tS), collected from healthy nu/nu mice 24 h after a treatment with 25 mg/kg LMS, was administered i.p. to 6-to 8-wk-old female C3H/He mice, at doses of either 0.2 or 0.5 ml, simultaneously to an i.e. immunization with 10 e SRC. Normal mouse serum (NMS) was sampled from untreated healthy nu/nu mice. Limulus assays were negative, indicating less than 0.5 ng endotoxin in 1 ml of these sera.
[gM-and IgG-antibody PFC were evaluated as described for Table II LMS or DTC exert their activity through an indirect pathway. They induce a nonthymic cellular system to produce a factor released in the serum. This factor, in turn, induced T-cell differentiation and activation. In current studies, hepatocytes or macrophages are candidates for the release of such a factor.
Our results are compatible with a function of epithelial thymus which could be, in essence, the release of a hormone allowing a still unidentified cell system to synthesize and excrete a factor that supplies the signal for T-cell differentiation. Thymectomy or genetic deficiency of thymus development will suppress the production of the thymic hormone, therefore suppressing excretion of the socalled "thymic-factors." In vivo treatment with sulphur derivatives, LMS or DTC, can substitute in immune events for an alleged thymic hormone.
Summary
Levamisole and sodium diethyldithiocarbamate can induce in vivo thymocyte differentiation from precursor spleen cells of nu/nu mice and evoke indirect plaque-forming cells in nude mice immunized with sheep red cells. These sulphur drugs induce in thymusless mice the production of a serum factor which transfer in vivo immune enhancement and in vitro thymocyte differentiation. In vivo treatment with sulphur derivative can substitute for an alleged thymice hormone.
